---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-036179"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:52:11.894961+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Foghorn Therapeutics Q3 net loss narrows to $14.3M; cash runway into H1 2026

## Summary
- Net loss $14.3M vs $25.8M YoY; collaboration revenue $17.5M incl. Merck termination.
- Cash, equivalents, marketable securities $259.9M as of Sept 30; runway into H1 2026.
- First patient dosed in FHD-286 combo study in AML; data expected H2 2024.
- Transitioned BRM Selective inhibitor program to Loxo@Lilly under collaboration.
- Preclinical data for EP300 and CBP selective degraders show tumor growth inhibition and no thrombocytopenia.

## SEC filing metadata
- accession: 0001628280-23-036179
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828023036179/0001628280-23-036179-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828023036179/fhtx-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-036179
- JSON: https://secwatch.observer/filing/0001628280-23-036179.json
- Plain text: https://secwatch.observer/filing/0001628280-23-036179.txt

## Key facts
- Earnings Releases
  Foghorn Therapeutics Inc. reported quarter ended September 30, 2023 results: revenue $17.5 million, net income $14.3 million.
  - Period: quarter ended September 30, 2023
  - Revenue: $17.5 million
  - Net income: $14.3 million
  - Result: reported results
  source text: $259.9 million in c ash, cash equivalents and marketable securities, which provides cash runway into the first half of 2026 . • Collaboration Revenues. Collaboration revenue was $17.5 million for the three months ended September 30, 2023, compared to $6.6 million for the three months ended September 30, 2022. The increase year-over-year was primarily driven by revenue
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822462/000162828023036179/0001628280-23-036179-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.